Ashland Inc.

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: $200M FCF base (~TTM $206M); 4% growth yrs1-5, 3% yrs6-10; 8.5% discount rate; 2.5% terminal growth; less $1,036M net debt; 45.79M shares outstanding.

Reasoning: Ashland is a mature specialty-chemicals producer (Life Sciences, Personal Care, Specialty Additives, Intermediates) with modest but stable organic growth and a leveraged but manageable balance sheet following a weak FY2025.